AMPK: Energy sensor and survival mechanism in the ischemic heart

Trends in Endocrinology and Metabolism

Volumn 26, Issue 8, 2015, Pages 422-429

  Qi, Dake ^a   Young, Lawrence H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ACETYL COENZYME A CARBOXYLASE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; ADIPOCYTOKINE; CARNITINE PALMITOYLTRANSFERASE I; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; DISULFIDE; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MACROPHAGE MIGRATION INHIBITION FACTOR; MALONYL COENZYME A; METFORMIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE LKB1; RAB PROTEIN; REACTIVE OXYGEN METABOLITE; THIOREDOXIN 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1;

ACETYLATION; ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; APOPTOSIS; AUTOCRINE EFFECT; AUTOPHAGY; CELL SURVIVAL; ENDOPLASMIC RETICULUM STRESS; ENERGY METABOLISM; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; GLYCOGEN SYNTHESIS; GLYCOLYSIS; HEART INFARCTION; HEART MITOCHONDRION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE NECROSIS; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HEART STRESS; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTON SODIUM EXCHANGE; REPERFUSION INJURY; REVIEW; SODIUM CALCIUM EXCHANGE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ANIMAL; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PHYSIOLOGY;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY;

EID: 84938285544     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2015.05.010     Document Type: Review

References (92)

1. Zaha V.G., Young L.H. AMP-activated protein kinase regulation and biological actions in the heart. Circ. Res. 2012, 111:800-814.
2. Hardie D.G., Carling D. The AMP-activated protein kinase - fuel gauge of the mammalian cell?. Eur. J. Biochem. 1997, 246:259-273.
3. Minokoshi Y., et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415:339-343.
4. Yamauchi T., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002, 8:1288-1295.
5. Russell R.R., et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J. Clin. Invest. 2004, 114:495-503.
6. Kudo N., et al. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J. Biol. Chem. 1995, 270:17513-17520.
7. Marsin A.S., et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr. Biol. 2000, 10:1247-1255.
8. Russell R.R., et al. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am. J. Physiol. 1999, 277:H643-H649.
9. Kim A.S., et al. A small molecule AMPK activator protects the heart against ischemia-reperfusion injury. J. Mol. Cell. Cardiol. 2011, 51:24-32.
10. Calvert J.W., et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 2008, 57:696-705.
11. Kim A.S., et al. AMP-activated protein kinase: a core signalling pathway in the heart. Acta Physiol. 2009, 196:37-53.
12. Li J., et al. Activation of AMPK alpha- and gamma-isoform complexes in the intact ischemic rat heart. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1927-H1934.
13. Pinter K., et al. Embryonic expression of AMPK γ subunits and the identification of a novel γ2 transcript variant in adult heart. J. Mol. Cell. Cardiol. 2012, 53:342-349.
14. Kim M., et al. AMPK isoform expression in the normal and failing hearts. J. Mol. Cell. Cardiol. 2012, 52:1066-1073.
15. Xiao B., et al. Structure of mammalian AMPK and its regulation by ADP. Nature 2011, 472:230-233.
16. Gowans G.J., et al. AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metab. 2013, 18:556-566.
17. Oakhill J.S., et al. AMPK is a direct adenylate charge-regulated protein kinase. Science 2011, 332:1433-1435.
18. Hardie D.G., et al. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 2012, 13:251-262.
19. Hawley S.A., et al. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J. Biol. Chem. 1996, 271:27879-27887.
20. Sakamoto K., et al. Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKα2 but not AMPKα1. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E780-E788.
21. 2+/calmodulin-dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2005, 2:21-33.
22. Momcilovic M., et al. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J. Biol. Chem. 2006, 281:25336-25343.
23. Hawley S.A., et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2003, 2:28.
24. Wang J., et al. Activated protein C protects against myocardial ischemic/reperfusion injury through AMP-activated protein kinase signaling. J. Thromb. Haemost. 2011, 9:1308-1317.
25. Qi D., et al. The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury. J. Clin. Invest. 2014, 124:3540-3550.
26. Xie M., et al. A pivotal role for endogenous TGF-β-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:17378-17383.
27. Pulinilkunnil T., et al. Adrenergic regulation of AMP-activated protein kinase in brown adipose tissue in vivo. J. Biol. Chem. 2011, 286:8798-8809.
28. Kovacic S., et al. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J. Biol. Chem. 2003, 278:39422-39427.
29. Djouder N., et al. PKA phosphorylates and inactivates AMPKα to promote efficient lipolysis. EMBO J. 2010, 29:469-481.
30. 485/491. J. Biol. Chem. 2006, 281:5335-5340.
31. Davies S.P., et al. 5'-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. FEBS Lett. 1995, 377:421-425.
32. Lin Y.Y., et al. Functional dissection of lysine deacetylases reveals that HDAC1 and p300 regulate AMPK. Nature 2012, 482:251-255.
33. Lan F., et al. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J. Biol. Chem. 2008, 283:27628-27635.
34. Shao D., et al. A redox-dependent mechanism for regulation of AMPK activation by thioredoxin1 during energy starvation. Cell Metab. 2014, 19:232-245.
35. Weiss J., Hiltbrand B. Functional compartmentation of glycolytic versus oxidative metabolism in isolated rabbit heart. J. Clin. Invest. 1985, 75:436-447.
36. Kramer H.F., et al. Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. Diabetes 2006, 55:2067-2076.
37. Samovski D., et al. Insulin and AMPK regulate FA translocase/CD36 plasma membrane recruitment in cardiomyocytes via Rab GAP AS160 and Rab8a Rab GTPase. J. Lipid Res. 2012, 53:709-717.
38. Fukuda M. TBC proteins: GAPs for mammalian small GTPase Rab?. Biosci. Rep. 2011, 31:159-168.
39. Ishikura S., et al. Rabs 8A and 14 are targets of the insulin-regulated Rab-GAP AS160 regulating GLUT4 traffic in muscle cells. Biochem. Biophys. Res. Commun. 2007, 353:1074-1079.
40. Sano H., et al. Insulin-stimulated GLUT4 protein translocation in adipocytes requires the Rab10 guanine nucleotide exchange factor Dennd4C. J. Biol. Chem. 2011, 286:16541-16545.
41. Yang J., Holman G.D. Insulin and contraction stimulate exocytosis, but increased AMP-activated protein kinase activity resulting from oxidative metabolism stress slows endocytosis of GLUT4 in cardiomyocytes. J. Biol. Chem. 2005, 280:4070-4078.
42. Nielsen J.N., et al. Role of 5'AMP-activated protein kinase in glycogen synthase activity and glucose utilization: insights from patients with McArdle's disease. J. Physiol. 2002, 541:979-989.
43. Halse R., et al. Regulation of glycogen synthase by glucose and glycogen: a possible role for AMP-activated protein kinase. Diabetes 2003, 52:9-15.
44. An D., et al. The metabolic "switch" AMPK regulates cardiac heparin-releasable lipoprotein lipase. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E246-E253.
45. Zordoky B.N., et al. AMPK-dependent inhibitory phosphorylation of ACC is not essential for maintaining myocardial fatty acid oxidation. Circ. Res. 2014, 115:518-524.
46. Dyck J.R., Lopaschuk G.D. AMPK alterations in cardiac physiology and pathology: enemy or ally?. J. Physiol. 2006, 574:95-112.
47. Wang Y., et al. AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation 2009, 119:835-844.
48. Costa R., et al. Activated protein C modulates cardiac metabolism and augments autophagy in the ischemic heart. J. Thromb. Haemost. 2012, 10:1736-1744.
49. Ma Y., et al. Antithrombin up-regulates AMP-activated protein kinase signalling during myocardial ischaemia/reperfusion injury. Thromb. Haemost. 2015, 113:338-349.
50. Matsui Y., et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ. Res. 2007, 100:914-922.
51. Takagi H., et al. AMPK mediates autophagy during myocardial ischemia in vivo. Autophagy 2007, 3:405-407.
52. Kim J., et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011, 13:132-141.
53. Herrero-Martin G., et al. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 2009, 28:677-685.
54. Kaufman R.J. Orchestrating the unfolded protein response in health and disease. J. Clin. Invest. 2002, 110:1389-1398.
55. Terai K., et al. AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol. Cell. Biol. 2005, 25:9554-9575.
56. Oyadomari S., Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 2004, 11:381-389.
57. Nakagawa T., et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000, 403:98-103.
58. Urano F., et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 2000, 287:664-666.
59. Paiva M.A., et al. Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H2123-H2134.
60. Miller E.J., et al. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 2008, 451:578-582.
61. Folmes C.D., et al. Suppression of 5'-AMP-activated protein kinase activity does not impair recovery of contractile function during reperfusion of ischemic hearts. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H313-H321.
62. Xing Y., et al. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative α2 subunit of AMP-activated protein kinase. J. Biol. Chem. 2003, 278:28372-28377.
63. Zarrinpashneh E., et al. Role of the α2-isoform of AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H2875-H2883.
64. Carvajal K., et al. Dual cardiac contractile effects of the α2-AMPK deletion in low-flow ischemia and reperfusion. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H3136-H3147.
65. Wang J., et al. Limiting cardiac ischemic injury by pharmacological augmentation of macrophage migration inhibitory factor-AMP-activated protein kinase signal transduction. Circulation 2013, 128:225-236.
66. Morrison A., et al. Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H895-H902.
67. Chin J.T., et al. A novel cardioprotective agent in cardiac transplantation: metformin activation of AMP-activated protein kinase decreases acute ischemia-reperfusion injury and chronic rejection. Yale J. Biol. Med. 2011, 84:423-432.
68. Galinanes M., et al. Acadesine and myocardial protection. Studies of time of administration and dose-response relations in the rat. Circulation 1992, 86:598-608.
69. Rosenkranz E.R., et al. Biochemical studies: failure of tissue adenosine triphosphate levels to predict recovery of contractile function after controlled reperfusion. J. Thorac. Cardiovasc. Surg. 1986, 92:488-501.
70. Mangano D.T. Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. JAMA 1997, 277:325-332.
71. Shimano M., et al. Cardiokines: recent progress in elucidating the cardiac secretome. Circulation 2012, 126:e327-e332.
72. Welford S.M., et al. HIF1alpha delays premature senescence through the activation of MIF. Genes Dev. 2006, 20:3366-3371.
73. Ma H., et al. Impaired macrophage migration inhibitory factor-AMP-activated protein kinase activation and ischemic recovery in the senescent heart. Circulation 2010, 122:282-292.
74. Qi D., et al. Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. J. Clin. Invest. 2009, 119:3807-3816.
75. Liehn E.A., et al. Compartmentalized protective and detrimental effects of endogenous macrophage migration-inhibitory factor mediated by CXCR2 in a mouse model of myocardial ischemia/reperfusion. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2180-2186.
76. Merk M., et al. D-Dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. Cytokine 2012, 59:10-17.
77. Li J., et al. Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:16133-16138.
78. Ogura Y., et al. Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models. Circulation 2012, 126:1728-1738.
79. Shi Y., Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
80. Lara-Pezzi E., et al. Expression of follistatin-related genes is altered in heart failure. Endocrinology 2008, 149:5822-5827.
81. Oshima Y., et al. Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation 2008, 117:3099-3108.
82. Shibata R., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 2005, 11:1096-1103.
83. Kambara T., et al. C1q/TNF-related protein 9 protects against acute myocardial injury through an AdipoR1-AMPK dependent mechanism. Mol. Cell. Biol. 2015, 35:2173-2185.
84. Kataoka Y., et al. Omentin prevents myocardial ischemic injury through AMP-activated protein kinase- and Akt-dependent mechanisms. J. Am. Coll. Cardiol. 2014, 63:2722-2733.
85. Li J., et al. AMP-activated protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart. Circ. Res. 2005, 97:872-879.
86. Morrison A., et al. Sestrin2 promotes LKB1-mediated AMPK activation in the ischemic heart. FASEB J. 2015, 29:408-417.
87. Sriwijitkamol A., et al. Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study. Diabetes 2007, 56:836-848.
88. Ko H.J., et al. Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes 2009, 58:2536-2546.
89. Xie Z., et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 2011, 60:1770-1778.
90. Kusmic C., et al. Improved myocardial perfusion in chronic diabetic mice by the up-regulation of pLKB1 and AMPK signaling. J. Cell. Biochem. 2010, 109:1033-1044.
91. Ruderman N.B., et al. AMPK, insulin resistance, and the metabolic syndrome. J. Clin. Invest. 2013, 123:2764-2772.
92. Seo-Mayer P.W., et al. Preactivation of AMPK by metformin may ameliorate the epithelial cell damage caused by renal ischemia. Am. J. Physiol. Renal Physiol. 2011, 301:F1346-F1357.